Persistence of Airway Inflammation and Remodeling in Subjects With Symptomatic or Complete Asthma Remission

NCT00526019 | Completed

• 1 other identifier: HL-07-20088
• Study Type: observational
• Target: 85
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims at determining the patterns of asthma remission, the prevalence of these different patterns, the various factors associated with such remissions and possible recurrences of asthma, in order to determine the mechanisms involved in these processes. The investigators therefore want to document these specificities in subjects in complete remission of their asthma, and those in only symptomatic remission of their asthma, in comparison with mildly symptomatic asthmatic subjects and healthy controls.

Conditions

Asthma

Keywords

remission of asthma

Study Arms (4)

Complete remission of their asthma

Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (\>16 mg/ml) for more than two years (with no current treatment).

Symptomatic remission ofasthma

Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine \<16 mg/ml)

Current asthma (mild asthma)

Subjects with current asthma (Mild asthma)

Healthy controls

Healthy controls

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects wiil be offered to volunteer from advertisements in newspaper. Subjects with asthma or in remission of asthma from primary care clinics will be offered to participate.

You may qualify if:

• In remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and (for complete remission) an optimal pulmonary function (FEV1 \> 90%) and normal PC20 methacholine for more than two years (with no current treatment).
• With a proven past history of asthma from medical files (reversible airway obstruction (\> 12% FEV1 after bronchodilator or 20% by other means) proven by spirometry, PEF measures or methacholine challenge according to current criteria + previous symptoms and asthma medication use), having no more asthma symptoms and not having used asthma medication for more than 2 years.
• Agree to sign the consent form.
• No other condition that could interfere with the study measurements.

You may not qualify if:

• Unable to adhere to the protocol requirements.
• Other current respiratory disease.
• Upper or lower respiratory tract infection or use of antibiotics \< 1 month.
• Use of oral corticosteroids within the last 3 months.
• Signs or symptoms of progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

Sponsors & Collaborators

• Laval University: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Louis-Philippe Boulet, MD

  Hôpital Laval

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, FRCPC, FCCP

Study Record Dates

• First Submitted: September 5, 2007
• First Posted: September 6, 2007
• Study Start: September 1, 2007
• Primary Completion: June 1, 2011
• Study Completion: February 1, 2012
• Last Updated: February 22, 2012

Record last verified: 2012-02